NCT04423991 (IDENTIFY) is a NA clinical trial of COViage in COVID-19, sponsored by Dascena.

Who is sponsoring NCT04423991?

NCT04423991 is sponsored by Dascena.

What drugs are being tested in NCT04423991?

Interventions in NCT04423991: COViage.

What condition does NCT04423991 study?

NCT04423991 studies COVID-19, Coronavirus, Mortality.

Is NCT04423991 still recruiting?

NCT04423991 is currently completed. Last updated 9 June 2020.

Last reviewed 2020-06-09 · How we verify

NCT04423991: IDENTIFY

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning

Completed NA Last updated 9 June 2020

What this trial tests

NA trial testing COViage in COVID-19 in 290 participants. Completed in 4 June 2020.

Timeline

10 March 2020

Primary endpoint
4 June 2020

4 June 2020

Quick facts

Lead sponsor	Dascena
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	290
Start date	10 March 2020
Primary completion	4 June 2020
Estimated completion	4 June 2020
Sites	1 location across United States

Drugs / interventions tested

COViage

Conditions studied

COVID-19 — all drugs for COVID-19 →
Coronavirus — all drugs for Coronavirus →
Mortality — all drugs for Mortality →

Sponsor

Dascena

Who can join

Eligibility, any sex, with COVID-19 or Coronavirus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study was to assess the performance of a machine learning algorithm which identifies patients for whom hydroxychloroquine treatment is associated with predicted survival.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

The application of artificial intelligence and data integration in COVID-19 studies: a scoping review.
Guo Y, Zhang Y, Lyu T, Prosperi M, et al · · 2021 · cited 20× · PMID 34151987 · DOI 10.1093/jamia/ocab098
Cellular and Molecular Immunology Approaches for the Development of Immunotherapies against the New Coronavirus (SARS-CoV-2): Challenges to Near-Future Breakthroughs.
Melgaço JG, Brito E Cunha D, Azamor T, da Silva AMV, et al · · 2020 · cited 10× · PMID 33426096 · DOI 10.1155/2020/8827670
Is Machine Learning a Better Way to Identify COVID-19 Patients Who Might Benefit from Hydroxychloroquine Treatment?-The IDENTIFY Trial.
Burdick H, Lam C, Mataraso S, Siefkas A, et al · · 2020 · cited 4× · PMID 33256141 · DOI 10.3390/jcm9123834

Verify or expand the search:

Other trials of COViage

Trials testing the same drug.

NCT04358510 — COVID-19 Mortality Prediction Model · completed
NCT04390516 — Respiratory Decompensation and Model for the Triage of COVID-19 Patients · NA · completed

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Dascena trials

Trials by the same sponsor.

NCT03734484 — Gram Type Infection-Specific Sepsis Identification Using Machine Learning · Phase 2 · withdrawn
NCT03752489 — Unsupervised Machine Learning for Clustering of Septic Patients to Determine Optimal Treatment · Phase 2 · unknown
NCT04005001 — Machine Learning Sepsis Alert Notification Using Clinical Data · Phase 2 · unknown
NCT04358510 — COVID-19 Mortality Prediction Model · completed
NCT04358536 — Classification of COVID-19 Infection in Posteroanterior Chest X-rays · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04423991 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dascena
Last refreshed: 9 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04423991.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing